


ASC Zerrecik Teknolojisi ile COVID-19 Aşısı Üretimi

Prof. Dr. Nesrin Özören

17.12.2020

RBD veya RBD kısımları ile oluşturulmuş 2 aşı adayı




1. RBM-ASC
2. tRBD2-ASC

RBD: Receptor binding domain of SARS CoV-2
RBM: Receptor binding motif of RBD
tRBD2: kesik RBD

RBM içeren ASC Zerreciklerinin Geliştirilmesi

RBM-ASC

DAPI





HEK293FT




WCL
2500g Pellet
2500g Sup

RBM-ASC

WCL
2500g Pellet
2500g Sup
300g Gravity Pellet
300g Pellet
300g Sup
RBM-ASC
500g Sup




tRBD2 İçeren ASC Zerreciklerinin Geliştirilmesi




RBM-ASC & tRBD2-ASC Zerrecikleri Aşılama Planı




40 µg RBD veya muadili antijen 40 µg veya daha olacak şekilde enjekte edilmiştir.



PBS





RBD



PBS veya sadece RBD enjekte edilen fareler 3. enjeksiyon sonrasında da RBD'ye özgü IgG yanıtı göstermemişlerdir.

2 Aşı Adayı da RBD'ye Özgü IgG Yanıtı Oluşturmaktadır



ASC zerrecikleri ile sunulan antijen Alum ve Freund's adjuvanlarına kıyasla daha iyi yanıt vermiştir.



Nesrin Özören, PhD

İlke Süder, MSc

Hafize Özen Kaya, MSc

Davod Khalafkhany, MSc

Efe Elbeyli, MSc

Sevgi Çıracı, BSc

Hilal Ok, BSc

Elif Öykü Çakır, BSc

Elif Eren, PhD

Tolga Sütü, PhD

Cevriye Pamukçu, MSc

Elif Çelik, MSc

Zeynep Ergün, BSc

Zeynep Karahan, BSc

Gizem Dinler Doğanay, PhD

Özge Tatlı, MSc

Ezgi Baştürk, MSc

Baran Dingiloğlu, MSc